NCT01310309

EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease

EXecutive Registry: XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 400 (actual)
• Sponsor: Abbott Medical Devices · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary Artery Disease (MVD).

Detailed description

This is a clinical evaluation of the XIENCE V® everolimus eluting coronary stent system as a revascularization treatment of patients with multi-vessel coronary artery disease (MVD-CAD). The sutdy is composed of two parts: A Randomized Controlled Trial, outlined in a separate posting and the registry portion of this study, which is as follows: -A prospective controlled registry to analyze the clinical efficacy and safety at mid and long-term follow-up in patients with MVD treated with the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).

Conditions

• Coronary Disease
• Coronary Artery Disease
• Coronary Artery Stenosis
• Coronary Artery Restenosis

Interventions

Type	Name	Description
DEVICE	Coronary artery placement of a drug-eluting stent	Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)

Timeline

• Start date: 2007-09-01
• Primary completion: 2010-10-01
• Completion: 2011-06-01
• First posted: 2011-03-08
• Last updated: 2012-12-21

Locations

23 sites across 1 country: Italy